**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)	

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 	

**Dummy YEAR** Dummy D, Doe J, Doe A. Pharmackoniteic study of COMPOUND. JOURNAL. YEAR Mon;ISSUE:PAGES. doi: DOI.	

**OSP PK Database** (https://github.com/Open-Systems-Pharmacology/Database-for-observed-data)



%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%



## ***Clarithromycin-Midazolam-DDI***

**Gorski 1998** Gorski, J. C., Jones, D. R., Haehner‐Daniels, B. D., Hamman, M. A., O'Mara Jr, E. M., & Hall, S. D. (1998). The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. *Clinical Pharmacology & Therapeutics*, *64*(2), 133-143.

**Gurley 2006** Gurley, B., Hubbard, M. A., Williams, D. K., Thaden, J., Tong, Y., Gentry, W. B., ... & Cheboyina, S. (2006). Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. *The Journal of Clinical Pharmacology*, *46*(2), 201-213.

**Gurley 2008a** Gurley, B. J., Swain, A., Hubbard, M. A., Hartsfield, F., Thaden, J., Williams, D. K., ... & Tong, Y. (2008). Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. *Clinical Pharmacology & Therapeutics*, *83*(1), 61-69.

**Markert 2013** Markert, C., Hellwig, R., Burhenne, J., Hoffmann, M. M., Weiss, J., Mikus, G., & Haefeli, W. E. (2013). Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. *European journal of clinical pharmacology*, *69*(10), 1785-1793.

**Prueksaritanont 2017** Prueksaritanont, T., Tatosian, D. A., Chu, X., Railkar, R., Evers, R., Chavez‐Eng, C., ... & Cai, X. (2017). Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. *Clinical Pharmacology & Therapeutics*, *101*(4), 519-530.

**Quinney 2008** Quinney, S. K., Haehner, B. D., Rhoades, M. B., Lin, Z., Gorski, J. C., & Hall, S. D. (2008). Interaction between midazolam and clarithromycin in the elderly. *British journal of clinical pharmacology*, *65*(1), 98-109.

**van Dyk 2018** van Dyk, M., Marshall, J. C., Sorich, M. J., Wood, L. S., & Rowland, A. (2018). Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. *European journal of clinical pharmacology*, *74*(7), 913-920.

**Yeates 1996** Yeates, R. A., Laufen, H., & Zimmermann, T. (1996). Interaction between midazolam and clarithromycin: comparison with azithromycin. *International journal of clinical pharmacology and therapeutics*, *34*(9), 400-405.



## ***Clarithromycin-Triazolam-DDI***

**Greenblatt 1998a** Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998 Sep;64(3):278-85.



## ***Erythromycin-Alfentanil-DDI***

**Bartkowski 1989** Bartkowski, R. R., Goldberg, M. E., Larijani, G. E., & Boerner, T. (1989). Inhibition of alfentanil metabolism by erythromycin. *Clinical Pharmacology & Therapeutics*, *46*(1), 99-102.

**Bartkowski 1993** Bartkowski, R. R., Goldberg, M. E., Huffnagle, S., & Epstein, R. H. (1993). Sufentanil disposition. Is it affected by erythromycin administration?. *Anesthesiology*, *78*(2), 260-265.



## ***Erythromycin-Alprazolam-DDI***

**Yasui 1996** Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Sugawara, K., ... & Ishizaki, T. (1996). A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. *Clinical Pharmacology & Therapeutics*, *59*(5), 514-519.



## ***Erythromycin-Midazolam-DDI***

**Carls 2014** Carls, A., Jedamzik, J., Witt, L., Hohmann, N., Burhenne, J., & Mikus, G. (2014). Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. *British journal of clinical pharmacology*, *78*(6), 1433-1440.

**Okudaira 2007** Okudaira, T., Kotegawa, T., Imai, H., Tsutsumi, K., Nakano, S., & Ohashi, K. (2007). Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. *The Journal of Clinical Pharmacology*, *47*(7), 871-876.

**Olkkola 1993** Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J. J., & Neuvonen, P. J. (1993). A potentially hazardous interaction between erythromycin and midazolam. *Clinical Pharmacology & Therapeutics*, *53*(3), 298-305.

**Swart 2002** Swart, E. L., van der Hoven, B., Johan Groeneveld, A. B., Touw, D. J., & Danhof, M. (2002). Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. *British journal of clinical pharmacology*, *53*(2), 133-139.

**Zimmermann 1996** Zimmermann, T., Yeates, R. A., Laufen, H., Scharpf, F., Leitold, M., & Wildfeuer, A. (1996). Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. *Arzneimittel-Forschung*, *46*(2), 213-217.



## ***Erythromycin-Triazolam-DDI***

**Greenblatt 1998** Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Counihan, M., Graf, J. A., Durol, A. L. B., ... & Shader, R. I. (1998). Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. *Clinical Pharmacology & Therapeutics*, *64*(3), 278-285.

**Phillips 1986** Phillips, J. P., Antal, E. J., & Smith, R. B. (1986). A pharmacokinetic drug interaction between erythromycin and triazolam. *Journal of clinical psychopharmacology*, *6*(5), 297-299.



## ***Fluvoxamine-Midazolam-DDI***

**Kashuba 1998** Kashuba AD1, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep;64(3):257-68.

**Lam 2003** Lam YW1, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003 Nov;43(11):1274-82.



## ***Fluvoxamine-Alprazolam-DDI***

**Fleishaker 1994** Fleishaker, J. C., & Hulst, L. K. (1994). A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. *European journal of clinical pharmacology*, *46*(1), 35-39.



## ***Itraconazole-Alprazolam-DDI***

**Yasui 1998** Yasui  N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K.  Effect of itraconazole on the single oral dose pharmacokinetics and  pharmacodynamics of alprazolam. Psychopharmacology (Berl). 1998  Oct;139(3):269-73.



## ***Itraconazole-Midazolam-DDI***

**Ahonen 1995** Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol. 1995 Sep;40(3):270-2.

**Backman 1998** Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998 Mar;54(1):53-8.

**Olkkola 1994** Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 May;55(5):481-5.

**Olkkola 1996** Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996 Mar;82(3):511-6.

**Prueksaritanont 2017** Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I,, Stoch SA. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017 Apr;101(4):519-530.

**Templeton 2010** Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010 Oct;88(4):499-505.

**Yu 2004** Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004 Aug;76(2):104-12.



## ***Itraconazole-Triazolam-DDI***

**Neuvonen 1996** Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther. 1996 Sep;60(3):326-31.

**Varhe 1994** Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):601-7.



## ***Rifampicin-Alfentanil-DDI***

**Kharasch 1997** Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology. 1997 Jul;87(1):36-50.

**Kharasch 2004** Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 Nov;76(5):452-66.

**Kharasch 2011** Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther. 2011 Jul;90(1):100-8.

**Kharasch 2011b** Kharasch ED, Vangveravong S, Buck N, London A, Kim T, Blood J, Mach RH. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clin Pharmacol Ther. 2011 Apr;89(4):562-70.

**Phimmasone 2001** Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther. 2001 Dec;70(6):505-17.



## ***Rifampicin-Alprazolam-DDI***

**Gashaw 2003** Gashaw, I., Kirchheiner, J., Goldammer, M., Bauer, S., Seidemann, J., Zoller, K., ... & Brockmöller, J. (2003). Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. *Clinical Pharmacology & Therapeutics*, *74*(5), 448-457.

**Schmider 1999** Schmider, J., Brockmöller, J., Arold, G., Bauer, S., & Roots, I. (1999). Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. *Pharmacogenetics*, *9*(6), 725-734.



## ***Rifampicin-Midazolam-DDI***

**Backman 1996** Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996 Jan;59(1):7-13.

**Backman 1998** Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998 Mar;54(1):53-8.

**Chung 2006** Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006 Apr;79(4):350-61.

**Eap 2004** Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004 Jun;60(4):237-46.

**Gorski 2003** Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003 Sep;74(3):275-87.

**Gurley 2006** Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006 Feb;46(2):201-13.

**Gurley 2008a** Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008 Jan;83(1):61-9.

**Kharasch 1997** Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology. 1997 Jul;87(1):36-50.

**Kharasch 2004** Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 Nov;76(5):452-66.

**Kharasch 2011** Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther. 2011 Jul;90(1):100-8.

**Kim 2018** Kim B, Lee J, Shin KH, Lee S, Yu KS, Jang IJ, Cho JY. Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. Clin Pharmacol Ther. 2018 May;103(5):879-887.

**Link 2008** Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, Krähenbühl S. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol. 2008 Oct;66(4):473-84.

**Phimmasone 2001** Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther. 2001 Dec;70(6):505-17.

**Prueksaritanont 2017** Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017 Apr;101(4):519-530.

**Reitman 2011** Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011 Feb;89(2):234-42.

**Shin 2013** Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 2013 Nov;94(5):601-9.

**Shin 2016** Shin KH, Ahn LY, Choi MH, Moon JY, Lee J, Jang IJ, Yu KS, Cho JY. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. AAPS J. 2016 Sep;18(5):1254-1261.

**Szalat 2007** Szalat A, Gershkovich P, Ben-Ari A, Shaish A, Liberman Y, Boutboul E, Gotkine M, Hoffman A, Harats D, Leitersdorf E, Meiner V. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim Biophys Acta. 2007 Jul;1771(7):839-44.

**van Dyk 2018** van Dyk M, Marshall JC, Sorich MJ, Wood LS, Rowland A. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. Eur J Clin Pharmacol. 2018 Jul;74(7):913-920.

**Yu 2004** Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004 Aug;76(2):104-12.



## ***Rifampicin-Triazolam-DDI***

**Villikka 1997** Villikka, K., Kivistö, K. T., Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1997). Triazolam is ineffective in patients taking rifampin. *Clinical Pharmacology & Therapeutics*, *61*(1), 8-14.

